Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab, Talquetamab, and JNJ-79635322 Combinations in Newly Diagnosed Multiple Myeloma
NCT05695508Phase 2Recruiting
- Start
- Dec 2022
- Primary completion
- Sep 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Trispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of teclistamab, talquetamab, ramantamig in multiple myeloma (MM). Started Dec 2022; status: recruiting.
02
Drugs
teclistamabtalquetamabramantamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05695508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05695508.